Patents by Inventor Iriny Botrous
Iriny Botrous has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240083861Abstract: Described herein are compounds that are HSD17B13 inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with HSD17B13 activity.Type: ApplicationFiled: September 29, 2021Publication date: March 14, 2024Inventors: Andrew R. Hudson, Steven P. Govek, Johnny Y. Nagasawa, Iriny Botrous, Nicholas D. Smith, Karensa L. Fasanya
-
Publication number: 20240034736Abstract: Described herein are compounds that are HSD17B13 inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with HSD17B13 activity.Type: ApplicationFiled: September 29, 2021Publication date: February 1, 2024Inventors: Andrew R. Hudson, Steven P. Govek, Johnny Y. Nagasawa, Iriny Botrous, Nicholas D. Smith, Karensa L. Fasanya
-
Publication number: 20230295178Abstract: Substituted furanopyrimidine chemical entities of Formula (I): wherein Ra has any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive therapies; modulating and treating disorders mediated by PDE1 activity or dopaminergic signaling; treating neurological disorders, CNS disorders, dementia, neurodegenerative diseases, and trauma-dependent losses of function; treating stroke, including cognitive and motor deficits during stroke rehabilitation; facilitating neuroprotection and neurorecovery; enhancing the efficiency of cognitive and motor training, including animal skill training protocols; and treating peripheral disorders, including cardiovascular, renal, hematological, gastroenterological, liver, cancer, fertility, and metabolic disorders.Type: ApplicationFiled: September 2, 2022Publication date: September 21, 2023Inventors: Brett Bookser, Iriny Botrous, Aaron Burns, DeMichael Chung, Brian Dyck, Andrew Kleinke, Dange Vijay Kumar, Margaret McCarrick, Nicholas Raffaele, Joe Tran, Michael Weinhouse
-
Publication number: 20230102554Abstract: Compounds are provided having the structure of Formula (I) or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, tautomer, isotope, or salt thereof, wherein A, X, R3, R5, R6, R7, R8, Y2, Y4, Y6, Y7, Y8, Y9, m, and n are as defined herein. Such compounds inhibit tyrosine kinase receptors, particularly the platelet derived growth factor receptor-alpha (PDGFR-?) and/or the platelet derived growth factor receptor-beta (PDGFR-?). Products containing such compounds, as well as methods for their use and preparation, are also provided.Type: ApplicationFiled: June 26, 2020Publication date: March 30, 2023Inventors: Luis Lopez, Craig Coburn, Martin W. Rowbottom, Iriny Botrous, Michelle Kasem
-
Patent number: 11434247Abstract: Substituted furanopyrimidine chemical entities of Formula (I): wherein Ra has any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive therapies; modulating and treating disorders mediated by PDE1 activity or dopaminergic signaling; treating neurological disorders, CNS disorders, dementia, neurodegenerative diseases, and trauma-dependent losses of function; treating stroke, including cognitive and motor deficits during stroke rehabilitation; facilitating neuroprotection and neurorecovery; enhancing the efficiency of cognitive and motor training, including animal skill training protocols; and treating peripheral disorders, including cardiovascular, renal, hematological, gastroenterological, liver, cancer, fertility, and metabolic disorders.Type: GrantFiled: November 26, 2018Date of Patent: September 6, 2022Assignee: Dart Neuroscience LLCInventors: Brett Bookser, Iriny Botrous, Aaron Burns, DeMichael Chung, Brian Dyck, Andrew Kleinke, Dange Vijay Kumar, Margaret McCarrick, Nicholas Raffaele, Joe Tran, Michael Weinhouse
-
Publication number: 20220002309Abstract: Described herein are compounds that are semicarbazide-sensitive amine oxidase (SSAO) inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in treating or preventing a liver disease or condition.Type: ApplicationFiled: October 23, 2019Publication date: January 6, 2022Inventors: Nicholas D. SMITH, Andrew R. HUDSON, Mi CHEN, Johnny Y. NAGASAWA, Iriny BOTROUS
-
Publication number: 20200181104Abstract: Described herein are compounds that are semicarbazide-sensitive amine oxidase (SSAO) inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in treating or preventing a liver disease or condition.Type: ApplicationFiled: February 14, 2020Publication date: June 11, 2020Inventors: Nicholas D. Smith, Andrew R. Hudson, Mi Chen, Johnny Y. Nagasawa, Iriny Botrous
-
Publication number: 20190177327Abstract: A chemical entity of Formula (I) or Formula (II): wherein Ra, Rb, Re, and Rf have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive treatments; modulating and treating disorders mediated by PDE1 activity or dopaminergic signaling; treating neurological disorders, CNS disorders, dementia, neurodegenerative diseases, and trauma-dependent losses of function; treating stroke, including cognitive and motor deficits during stroke rehabilitation; facilitating neuroprotection and neurorecovery; enhancing the efficiency of cognitive and motor training, including animal skill training protocols; and treating peripheral disorders, including cardiovascular, renal, hematological, gastroenterological, liver, cancer, fertility, and metabolic disorders.Type: ApplicationFiled: October 12, 2018Publication date: June 13, 2019Inventors: Brett Bookser, Iriny Botrous, Bryan Branstetter, Brian Dyck, Michael Weinhouse
-
Patent number: 8999981Abstract: The present invention relates to compounds and pharmaceutically acceptable salts of Formula (I): wherein X, R1, R2, R3, R4, R5, R6, R7, and R8 are as defined above. The invention further relates to pharmaceutical compositions comprising the compounds and pharmaceutically acceptable salts and to methods of treating diabetes mellitus and its complications (including in particular diabetic retinopathy, nephropathy or neuropathy), cancer, ischemia, inflammation, central nervous system disorders, cardiovascular disease, Alzheimer's disease and dermatological disease pression, viral diseases, inflammatory disorders, or diseases in which the liver is a target organ.Type: GrantFiled: January 6, 2012Date of Patent: April 7, 2015Assignees: Pfizer Inc., Pfizer Products Inc.Inventors: Iriny Botrous, Yufeng Hong, Hui Li, Kevin Kun-Chin Liu, Seiji Nukui, Min Teng, Eileen Valenzuela Tompkins, Chunfeng Yin
-
Publication number: 20120108588Abstract: The present invention relates to compounds and pharmaceutically acceptable salts of Formula (I): wherein X, R1, R2, R3, R4, R5, R6, R7, and R8 are as defined above. The invention further relates to pharmaceutical compositions comprising the compounds and pharmaceutically acceptable salts and to methods of treating diabetes mellitus and its complications (including in particular diabetic retinopathy, nephropathy or neuropathy), cancer, ischemia, inflammation, central nervous system disorders, cardiovascular disease, Alzheimer's disease and dermatological disease pression, viral diseases, inflammatory disorders, or diseases in which the liver is a target organ.Type: ApplicationFiled: January 6, 2012Publication date: May 3, 2012Applicant: Pfizer, Inc.Inventors: Iriny Botrous, Yufeng Hong, Hui Li, Kevin Kun-Chin Liu, Seiji Nukui, Min Teng, Eileen Valenzuela Tompkins, Chunfeng Yin
-
Patent number: 8114871Abstract: The present invention relates to compounds and pharmaceutically acceptable salts of Formula (I): wherein X, R1, R2, R3, R4, R5, R6, R7, and R8 are as defined above. The invention further relates to pharmaceutical compositions comprising the compounds and pharmaceutically acceptable salts and to methods of treating diabetes mellitus and its complications (including in particular diabetic retinopathy, nephropathy or neuropathy), cancer, ischemia, inflammation, central nervous system disorders, cardiovascular disease, Alzheimer's disease and dermatological disease pression, viral diseases, inflammatory disorders, or diseases in which the liver is a target organ.Type: GrantFiled: April 10, 2008Date of Patent: February 14, 2012Assignees: Pfizer Inc., Pfizer Products Inc.Inventors: Iriny Botrous, Yufeng Hong, Hui Li, Kevin Kun-Chin Liu, Seiji Nukui, Min Teng, Eileen Valenzuela Tompkins, Chunfeng Yin
-
Patent number: 8106197Abstract: Aminopyridine and aminopyrazine compounds of formula (1), compositions including these compounds, and methods of their use are provided. Preferred compounds of formula 1 have activity as protein kinase inhibitors, including as inhibitors of c-MET.Type: GrantFiled: November 14, 2006Date of Patent: January 31, 2012Assignee: Pfizer Inc.Inventors: Jingrong Jean Cui, Dilip Bhumralkar, Iriny Botrous, Ji Yu Chu, Lee A. Funk, Cathleen Elizabeth Hanau, G. Davis Harris, Lei Jia, Joanne Johnson, Stephen A. Kolodziej, Pei-Pei Kung, Xiaoyuan (Sharon) Li, Jason (Qishen) Lin, Jerry Jialun Meng, Mitchell David Nambu, Christopher G. Nelson, Mason Alan Pairish, Hong Shen, Michelle Tran-Dube, Allison Walter, Fang-Jie Zhang, Jennifer Zhang
-
Publication number: 20100249128Abstract: The present invention relates to compounds and pharmaceutically acceptable salts of Formula (I): wherein X, R1, R2, R3, R4, R5, R6, R7, and R8 are as defined above. The invention further relates to pharmaceutical compositions comprising the compounds and pharmaceutically acceptable salts and to methods of treating diabetes mellitus and its complications (including in particular diabetic retinopathy, nephropathy or neuropathy), cancer, ischemia, inflammation, central nervous system disorders, cardiovascular disease, Alzheimer's disease and dermatological disease pression, viral diseases, inflammatory disorders, or diseases in which the liver is a target organ.Type: ApplicationFiled: April 10, 2008Publication date: September 30, 2010Inventors: Iriny Botrous, Yufeng Hong, Hui Li, Kevin Kun-Chin Liu, Seiji Nukui, Min Teng, Eileen Valenzuela Tompkins, Chunfeng Yin
-
Patent number: 7250417Abstract: The present invention relates to compounds of the Formulae (I)-(IV), wherein R1-R6, R11-R13, X and Y are defined herein, and their pharmaceutically acceptable salts.Type: GrantFiled: June 25, 2004Date of Patent: July 31, 2007Assignee: Sugen Inc.Inventors: Jingrong Cui, Iriny Botrous
-
Patent number: 7230098Abstract: Aminopyridine and aminopyrazine compounds of formula (1), compositions including these compounds, and methods of their use are provided.Type: GrantFiled: February 26, 2004Date of Patent: June 12, 2007Assignee: Sugen, Inc.Inventors: Jingrong Jean Cui, Dilip Bhumralkar, Iriny Botrous, Ji Yu Chu, Lee A. Funk, Cathleen Elizabeth Hanau, G. Davis Harris, Lei Jia, Joanne Johnson, Stephen A. Kolodziej, Pei-Pei Kung, Xiaoyuan (Sharon) Li, Jason (Qishen) Lin, Jerry Jialun Meng, Mitchell David Nambu, Christopher G. Nelson, Mason Alan Pairish, Hong Shen, Michelle Tran-Dube, Allison Walter, Fang-Jie Zhang, Jennifer Zhang
-
Publication number: 20070072874Abstract: Aminopyridine and aminopyrazine compounds of formula (1), compositions including these compounds, and methods of their use are provided. Preferred compounds of formula 1 have activity as protein kinase inhibitors, including as inhibitors of c-MET.Type: ApplicationFiled: November 14, 2006Publication date: March 29, 2007Inventors: Jingrong Cui, Dilip Bhumralkar, Iriny Botrous, Ji Chu, Lee Funk, Cathleen Hanau, G. Harris, Lei Jia, Joanne Johnson, Stephen Kolodziej, Pei-Pei Kung, Xiaoyuan Li, Jason Lin, Jerry Meng, Mitchell Nambu, Christopher Nelson, Mason Pairish, Hong Shen, Michelle Tran-Dube, Allison Walter, Fang-Jie Zhang, Jennifer Zhang
-
Publication number: 20050107391Abstract: The present invention relates to compounds of the Formulae (I)-(IV), wherein R1-R6, R11-R13, X and Y are defined herein, and their pharmaceutically acceptable salts. These compounds modulate the activity of c-Met and are therefore expected to be useful in the prevention and treatment of c-Met related disorders such as cancer.Type: ApplicationFiled: June 25, 2004Publication date: May 19, 2005Inventors: Jingrong Cui, Iriny Botrous
-
Publication number: 20050009840Abstract: Aminopyridine and aminopyrazine compounds of formula (1), compositions including these compounds, and methods of their use are provided. Preferred compounds of formula 1 have activity as protein kinase inhibitors, including as inhibitors of c-MET.Type: ApplicationFiled: February 26, 2004Publication date: January 13, 2005Inventors: Jingrong Cui, Dilip Bhumralkar, Iriny Botrous, Ji Chu, Lee Funk, Cathleen Hanau, G. Harris, Lei Jia, Joanne Johnson, Stephen Kolodziej, Pei-Pei Kung, Xiaoyuan Li, Jason Lin, Jerry Meng, Mitchell Nambu, Christopher Nelson, Mason Pairish, Hong Shen, Michelle Tran-Dube, Allison Walter, Fang-Jie Zhang, Jennifer Zhang